ATE365047T1 - N-terminal monopegylierte menschliche wachstumshormon-konjugate, verfahren zu ihrer herstellung und ihre anwendung - Google Patents

N-terminal monopegylierte menschliche wachstumshormon-konjugate, verfahren zu ihrer herstellung und ihre anwendung

Info

Publication number: ATE365047T1
Authority: AT; Austria
Prior art keywords: growth hormone; human growth; production; hgh; present
Prior art date: 2004-02-04

Application number

AT05702331T

Other languages

English (en)

Inventor

Rory Finn

Original Assignee

Pharmacia Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-02-04

Filing date

2005-01-24

Publication date

2007-07-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34886516&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE365047(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2005-01-24 Application filed by Pharmacia Corp filed Critical Pharmacia Corp

2007-07-15 Application granted granted Critical

2007-07-15 Publication of ATE365047T1 publication Critical patent/ATE365047T1/de

Links

102000002265 Human Growth Hormone Human genes 0.000 title abstract 5
108010000521 Human Growth Hormone Proteins 0.000 title abstract 5
239000000854 Human Growth Hormone Substances 0.000 title abstract 5
ZTQSAGDEMFDKMZ-UHFFFAOYSA-N Butyraldehyde Chemical group CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 abstract 1
102000018997 Growth Hormone Human genes 0.000 abstract 1
108010051696 Growth Hormone Proteins 0.000 abstract 1
239000002202 Polyethylene glycol Substances 0.000 abstract 1
230000009286 beneficial effect Effects 0.000 abstract 1
230000006806 disease prevention Effects 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
208000035475 disorder Diseases 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
239000000122 growth hormone Substances 0.000 abstract 1
230000002045 lasting effect Effects 0.000 abstract 1
102000035118 modified proteins Human genes 0.000 abstract 1
108091005573 modified proteins Proteins 0.000 abstract 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 abstract 1
COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 abstract 1
229920001223 polyethylene glycol Polymers 0.000 abstract 1
102000004169 proteins and genes Human genes 0.000 abstract 1
108090000623 proteins and genes Proteins 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Endocrinology (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Neurology (AREA)
Epidemiology (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Toxicology (AREA)
Biochemistry (AREA)
Psychiatry (AREA)
Immunology (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Virology (AREA)
Pain & Pain Management (AREA)
Communicable Diseases (AREA)
Gynecology & Obstetrics (AREA)
Reproductive Health (AREA)
Urology & Nephrology (AREA)

AT05702331T 2004-02-04 2005-01-24 N-terminal monopegylierte menschliche wachstumshormon-konjugate, verfahren zu ihrer herstellung und ihre anwendung ATE365047T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US10/771,895 US20040142870A1 (en)	2002-11-20	2004-02-04	N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof

Publications (1)

Publication Number	Publication Date
ATE365047T1 true ATE365047T1 (de)	2007-07-15

Family

ID=34886516

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT05702331T ATE365047T1 (de)	2004-02-04	2005-01-24	N-terminal monopegylierte menschliche wachstumshormon-konjugate, verfahren zu ihrer herstellung und ihre anwendung

Country Status (21)

Country	Link
US (1)	US20040142870A1 (de)
EP (2)	EP1915999A1 (de)
JP (3)	JP2007520544A (de)
KR (2)	KR20070039623A (de)
CN (1)	CN1929857A (de)
AT (1)	ATE365047T1 (de)
AU (1)	AU2005215250A1 (de)
BR (1)	BRPI0507427A (de)
CA (1)	CA2555772A1 (de)
CY (1)	CY1106723T1 (de)
DE (1)	DE602005001445T2 (de)
DK (1)	DK1715887T3 (de)
ES (1)	ES2286787T3 (de)
IL (1)	IL176998A0 (de)
NO (1)	NO20063926L (de)
PL (1)	PL1715887T3 (de)
PT (1)	PT1715887E (de)
RU (1)	RU2006128293A (de)
TW (2)	TW200529868A (de)
WO (1)	WO2005079838A1 (de)
ZA (2)	ZA200706349B (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030171285A1 (en) *	2001-11-20	2003-09-11	Finn Rory F.	Chemically-modified human growth hormone conjugates
DE60332358D1 (de) *	2002-09-09	2010-06-10	Hanall Pharmaceutical Co Ltd	Protease-resistente modifizierte interferon alpha polypeptide
KR20050093856A (ko)	2002-09-09	2005-09-23	넥타르 테라퓨틱스 에이엘, 코포레이션	수용성 중합체 알카날
US20040142870A1 (en) *	2002-11-20	2004-07-22	Finn Rory F.	N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof
JP5207590B2 (ja) *	2002-12-26	2013-06-12	マウンテンビューファーマシューティカルズ，インコーポレイテッド	増強された生物学的能力を有するインターフェロン−βのポリマー結合体
GEP20084487B (en) *	2002-12-26	2008-09-25	Mountain View Pharmaceuticals	Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof
WO2006023608A2 (en) *	2004-08-18	2006-03-02	Elixir Pharmaceuticals, Inc.	Growth-hormone secretagogues
JP2008515389A (ja) *	2004-08-20	2008-05-15	ノボノルディスクアクティーゼルスカブ	ヘモペキシン融合タンパク質
US7998930B2 (en)	2004-11-04	2011-08-16	Hanall Biopharma Co., Ltd.	Modified growth hormones
EP1850878A2 (de)	2005-02-10	2007-11-07	Novo Nordisk A/S	C-terminal-pegylierte wachstumshormone
US20060233740A1 (en) *	2005-03-23	2006-10-19	Bossard Mary J	Conjugates of an hGH moiety and a polymer
US7855279B2 (en)	2005-09-27	2010-12-21	Amunix Operating, Inc.	Unstructured recombinant polymers and uses thereof
EP1968625A2 (de) *	2005-12-15	2008-09-17	Laboratoires Serono SA	Neue chemokin-antagonisten
AU2007267798A1 (en) *	2006-05-26	2007-12-06	Ipsen Pharma S.A.S.	Methods for site-specific pegylation
US9840546B2 (en) *	2008-04-03	2017-12-12	Biosteed Gene Expression Tech. Co., Ltd.	Double-stranded polyethylene glycol modified growth hormone, preparation method and application thereof
EP2113256A1 (de)	2008-04-29	2009-11-04	Ascendis Pharma AS	Pegylierte rhGH-Verbindungen
MX344559B (es)	2008-04-29	2016-12-20	Ascendis Pharma As	Compuestos de hormona de crecimiento humana recombinante unidos al peg.
AR072850A1 (es) *	2008-07-31	2010-09-22	Pharmaessentia Corp	Conjugados peptido-polimero
ES2610356T3 (es)	2009-02-03	2017-04-27	Amunix Operating Inc.	Polipéptidos recombinantes extendidos y composiciones que comprenden los mismos
US8703717B2 (en) *	2009-02-03	2014-04-22	Amunix Operating Inc.	Growth hormone polypeptides and methods of making and using same
US8680050B2 (en) *	2009-02-03	2014-03-25	Amunix Operating Inc.	Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
US9849188B2 (en)	2009-06-08	2017-12-26	Amunix Operating Inc.	Growth hormone polypeptides and methods of making and using same
WO2011018515A1 (en) *	2009-08-14	2011-02-17	Novo Nordisk Health Care Ag	Method of purifying pegylated proteins
MX337432B (es)	2009-12-15	2016-03-04	Ascendis Pharma As	Composicion de la hormona del crecimiento seca enlazada transitoriamente a un portador del polimero.
CN102453089B (zh) *	2010-10-25	2014-06-04	北京凯因科技股份有限公司	重组集成干扰素变异体聚乙二醇偶联物的制备和应用
CA2857686C (en) *	2011-12-09	2023-01-17	Metabolic Pharmaceuticals Pty Ltd	Use of growth hormone fragments
CN102964588A (zh) *	2012-11-09	2013-03-13	河南工业大学	末端连接氨基苯丙酸的聚乙二醇的酸或活性酯的制法和应用
SG11201703870UA (en)	2014-11-18	2017-06-29	Ascendis Pharma Endocrinology Div As	Novel polymeric hgh prodrugs
PT3220892T (pt)	2014-11-21	2021-11-05	Ascendis Pharma Endocrinology Div A/S	Formas de dosagem de hormona do crescimento de longa ação
KR101599415B1 (ko)	2015-05-29	2016-03-03	(주)신명이앤씨	건축물 층간 바닥 전기 케이블 보호관
AU2020233198B2 (en)	2019-03-04	2025-05-15	Ascendis Pharma Endocrinology Division A/S	Long-acting growth hormone dosage forms with superior efficacy to daily somatropin
CN114539384B (zh) *	2020-11-19	2024-09-06	江苏众红生物工程创药研究院有限公司	聚乙二醇化长效生长激素及其制备方法和医药应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2003044056A2 (en) *	2001-11-20	2003-05-30	Pharmacia Corporation	Chemically-modified human growth hormone conjugates
US20040142870A1 (en) *	2002-11-20	2004-07-22	Finn Rory F.	N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof

2004
- 2004-02-04 US US10/771,895 patent/US20040142870A1/en not_active Abandoned
2005
- 2005-01-24 JP JP2006551943A patent/JP2007520544A/ja active Pending
- 2005-01-24 ZA ZA200706349A patent/ZA200706349B/xx unknown
- 2005-01-24 KR KR1020077007102A patent/KR20070039623A/ko not_active Withdrawn
- 2005-01-24 WO PCT/IB2005/000171 patent/WO2005079838A1/en not_active Ceased
- 2005-01-24 DE DE602005001445T patent/DE602005001445T2/de not_active Expired - Fee Related
- 2005-01-24 AT AT05702331T patent/ATE365047T1/de not_active IP Right Cessation
- 2005-01-24 KR KR1020067015733A patent/KR100776862B1/ko not_active Expired - Fee Related
- 2005-01-24 CN CNA2005800073938A patent/CN1929857A/zh active Pending
- 2005-01-24 RU RU2006128293/14A patent/RU2006128293A/ru not_active Application Discontinuation
- 2005-01-24 EP EP07110559A patent/EP1915999A1/de not_active Withdrawn
- 2005-01-24 PL PL05702331T patent/PL1715887T3/pl unknown
- 2005-01-24 ES ES05702331T patent/ES2286787T3/es not_active Expired - Lifetime
- 2005-01-24 PT PT05702331T patent/PT1715887E/pt unknown
- 2005-01-24 BR BRPI0507427-4A patent/BRPI0507427A/pt not_active IP Right Cessation
- 2005-01-24 AU AU2005215250A patent/AU2005215250A1/en not_active Abandoned
- 2005-01-24 CA CA002555772A patent/CA2555772A1/en not_active Abandoned
- 2005-01-24 DK DK05702331T patent/DK1715887T3/da active
- 2005-01-24 EP EP05702331A patent/EP1715887B1/de not_active Expired - Lifetime
- 2005-02-03 TW TW094103308A patent/TW200529868A/zh unknown
- 2005-02-03 TW TW096134157A patent/TW200812610A/zh unknown
2006
- 2006-07-20 IL IL176998A patent/IL176998A0/en unknown
- 2006-08-01 ZA ZA200606375A patent/ZA200606375B/xx unknown
- 2006-09-01 NO NO20063926A patent/NO20063926L/no not_active Application Discontinuation
2007
- 2007-07-12 CY CY20071100928T patent/CY1106723T1/el unknown
- 2007-08-15 JP JP2007211676A patent/JP2008001713A/ja not_active Withdrawn
- 2007-08-15 JP JP2007211682A patent/JP2008037872A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
RU2006128293A (ru)	2008-02-10
CA2555772A1 (en)	2005-09-01
IL176998A0 (en)	2006-12-10
EP1915999A1 (de)	2008-04-30
DE602005001445D1 (de)	2007-08-02
KR100776862B1 (ko)	2007-11-28
JP2007520544A (ja)	2007-07-26
ES2286787T3 (es)	2007-12-01
TW200812610A (en)	2008-03-16
ZA200706349B (en)	2008-06-25
TW200529868A (en)	2005-09-16
DE602005001445T2 (de)	2008-02-14
WO2005079838A1 (en)	2005-09-01
EP1715887A1 (de)	2006-11-02
EP1715887B1 (de)	2007-06-20
NO20063926L (no)	2006-10-30
PL1715887T3 (pl)	2007-12-31
AU2005215250A1 (en)	2005-09-01
ZA200606375B (en)	2007-11-28
JP2008001713A (ja)	2008-01-10
PT1715887E (pt)	2007-08-29
CN1929857A (zh)	2007-03-14
DK1715887T3 (da)	2007-09-17
JP2008037872A (ja)	2008-02-21
CY1106723T1 (el)	2012-05-23
BRPI0507427A (pt)	2007-06-26
KR20060120240A (ko)	2006-11-24
US20040142870A1 (en)	2004-07-22
KR20070039623A (ko)	2007-04-12

Legal Events

Date

Code

Title

Description

2007-10-15

UEP

Publication of translation of european patent specification

Ref document number: 1715887

Country of ref document: EP

2009-10-15

REN

Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
ATE365047T1 (de)	2007-07-15	N-terminal monopegylierte menschliche wachstumshormon-konjugate, verfahren zu ihrer herstellung und ihre anwendung
MX377317B (es)	2025-03-04	Compuestos de hormona de crecimiento humana recombinante unidos a peg.
AP2004003050A0 (en)	2004-06-30	Chemically modified human growth hormone conjugates
WO2003001982A3 (en)	2003-11-20	Physiological tissue repair and functional organ regeneration by cultivation of regenerative stem cells in vivo and in situ
TW200612985A (en)	2006-05-01	Immunoglobulins
YU71901A (sh)	2005-07-19	NOVE VRSTE LEKOVITIH KOMPOZICIJA NA BAZI JEDINJENJA KOJA DELUJU ANTIHOLINERGIJSKI I beta-MIMETIKA
ATE405564T1 (de)	2008-09-15	1h-imidazoä4,5-cüchinolinderivate zur behandlung von protein kinase-abhängigen krankheiten
WO2006093348A3 (en)	2006-11-16	Method and composition for treating peripheral vascular diseases
WO2006034373A3 (en)	2006-11-02	Variants and chemically-modified variants of phenylalanine ammonia-lyase
DE60039878D1 (de)	2008-09-25	XENON ALS NMDA-ANTOGONIST zur Neuroprotektion
EP2107071A3 (de)	2009-12-30	Anti-Epcam-Immunoglobuline
WO2005080338A8 (en)	2006-10-05	New pharmaceutical compositions based on benzilic acid esters and soluble tnf receptor fusion proteins
MX366496B (es)	2019-07-11	Metodos para preparar composiciones farmaceuticas que comprenden acetato de eslicarbazepina y metodos de uso.
ATE330596T1 (de)	2006-07-15	Verwendung von 3-bezoylphenylessigsäure-derivaten zur behandlung von netzhauterkrankungen
DE60330501D1 (de)	2010-01-21	Verfahren zur behandlung von verletzungen des nervensystems in verbindung mit einer blutung
DE60227367D1 (de)	2008-08-14	Modifizierter granulozyten stimulierender factor (g-csf) mit verringerter immunogenität
TW200512003A (en)	2005-04-01	Enhanced method of treatment of growth disorders
SE0100873D0 (sv)	2001-03-13	Method of treatment
TW200517395A (en)	2005-06-01	Process for preparing famciclovir
WO2004050703A8 (en)	2004-09-23	Splice variant of the human pituitary growth hormone
WO2005005668A3 (en)	2005-09-09	Diagnosis and treatment methods related to aging (8a)
WO2003096964A3 (en)	2004-05-06	Means for use in treating diseases correlated with or caused by non-physiological levels of microtubule-associated pp2ac
WO2002010749A1 (en)	2002-02-07	Method of screening substance for preventing or treating diseases in association with il-6 family cytokine receptor malfunction
WO2007047235A3 (en)	2007-07-12	Compositions and methods for treatment of airway hypersecretion
WO2005056574A3 (en)	2006-02-16	Method and vaccine comprising copolymer 1 for treatment of psychiatric disorders